Adipose tissue mesenchymal stem cells and methods of use to treat or inhibit uterine disorders

Abstract

There is a high stem cell therapy potential in the field of reproductive disorders. Endometriosis is a common finding in women with infertility. In addition endometriosis is the major problem in the veterinary field. In the disclosed invention we provide a method of application and use of adipose tissue derived stem cell to treat fertility and pregnancy related disorders, especially endometriosis in mammalian objects.

1 . A method of treating or inhibiting a uterine disorder or injury in a mammalian female subject, the method comprising transplanting adipose tissue derived mesenchymal stem cells (AT-MSCs) into the uterus of the mammalian female in need thereof,
 wherein the method positively remodels the endometrial tissue of the mammalian subject.   
     
     
         2 . The method of claim  0 , wherein the mammalian female is human. 
     
     
         3 . The method of  claim 1 , wherein the uterine disorder or injury is selected from the group consisting of endometriosis, atypical endometrium, poor endometrium, thin uterine lining, uterine polyps and fibroids, intrauterine adhesions, uterine cavity scar tissue, and uterine related infertility or pregnancy problems. 
     
     
         4 . The method of claim  0 , wherein the subject is an animal. 
     
     
         5 . The method of claim  0 , wherein the animal is selected from the group consisting of a cow, a sheep, a goat, and a mare. 
     
     
         6 . The method of claim  0 , wherein the animal is a mare suffering from equine endometriosis. 
     
     
         7 . The method of  claim 1 , wherein the transplanted AT-MSCs were cryopreserved in liquid nitrogen. 
     
     
         8 . The method of claim  0 , wherein the AT-MSCs are transplanted directly after thawing without additional culturing in vitro. 
     
     
         9 . The method of claim  0 , wherein the method improves the uterine environment prior to conception or in-vitro fertilization. 
     
     
         10 . (canceled) 
     
     
         11 . The method of  claim 1 , wherein remodeling the endometrial tissue is up to 7 days following intrauterine transplantation of AT-MSCs. 
     
     
         12 . The method of  claim 1 , wherein the method positively remodels the endometrial tissue up to 60 days following intrauterine transplantation of AT-MSCs. 
     
     
         13 . The method of  claim 1 , wherein the method stimulates the uterine environment of mammalian females having endometriosis, uterine disorders or injury, uterine related infertility or pregnancy problems. 
     
     
         14 . The method of  claim 1 , further comprising stimulating uterine epithelial and periglandular stromal cells of mammalian females with endometriosis, uterine disorders or injury, uterine related infertility or pregnancy problems. 
     
     
         15 . The method of  claim 1 , further comprising modulating the uterine expression of proteins selected from the group consisting of cytokeratin, vimentin, α-SMA and laminin in mammalian females with endometriosis, uterine disorders or injury, uterine related infertility or pregnancy problems. 
     
     
         16 . The method of  claim 1 , wherein the method decreases or prevents the development of pathological processes in the uterine. 
     
     
         17 . The method of  claim 1 , wherein the method decreases or prevents the development of fibrotic regions in the endometrium. 
     
     
         18 . The method of  claim 1 , wherein the method decreases or prevents uterine scarring. 
     
     
         19 . The method of  claim 1 , wherein the method increases uterine glandular epithelial cells proliferation. 
     
     
         20 . The method of  claim 1 , wherein the method decreases or prevents the recurrence of uterine injury. 
     
     
         21 . The method of  claim 1 , wherein the method reduces or prevents the development of atypical morphological and functional differentiation of glandular and periglandular endometrial stromal cells. 
     
     
         22 . The method of claim  0  wherein transplanting adipose tissue derived AT-MSCs in the uterine is done prior to hormonal therapy, concurrently with hormonal therapy or subsequently to hormonal therapy. 
     
     
         23 . The method of  claim 1 , further comprising administrating to the subject one or more systemic stem cell therapies. 
     
     
         24 . The method of  claim 1 , wherein the AT-MSCs are allogeneic. 
     
     
         25 . The method of  claim 1 , wherein transplanting adipose tissue derived AT-MSCs is performed without application of immunosuppressive protocols. 
     
     
         26 - 34 . (canceled)